Skip to main content
. 2022 Apr 2;10(6):1622–1634.e4. doi: 10.1016/j.jaip.2022.03.017

Figure 5.

Figure 5

SARS-CoV-2 anti-spike antibody titers (U/mL), shown in log scale and compared between initial series SARS-CoV-2 vaccination (red circles) and additional dose SARS-CoV-2 vaccination (green circles). Data are shown for the total boosted predominant antibody deficiency (PAD) cohort (n = 31) and compared with the matched healthy controls (n = 31) (A) and by PAD diagnosis (B). Symbols (A) represent unique individuals and bars represent geometric means (±95% confidence intervals) of total indicated patients (n). Symbols (B) represent geometric means (±95% confidence intervals) of total indicated patients (n). Shading represents the assay lower limit of reactivity. ∗∗∗P < .001; ∗∗∗∗P < .0001. ns, not significant.